SCHEMBL7452182

SCHEMBL7452182

N#Cc1ccc(CC(c2cnc[nH]2)N2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 2/20 0.50
CYP19A1 P11511 7/20 0.49
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SLC6A4 P31645 4/20 0.43
SLC6A2 P23975 3/20 0.43
OPRM1 P35372 1/20 0.43
OPRK1 P41145 1/20 0.43
OPRL1 P41146 1/20 0.43
HRH3 Q9Y5N1 1/20 0.41
SLC1A3 P43003 2/20 0.40
SLC1A2 P43004 2/20 0.40
KCNH2 Q12809 2/20 0.40
SLC1A1 P43005 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
CPA1 P15085 1/20 0.39
P2RX7 Q99572 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7134263 0.84 HRH3 (0.46) OPRD1CYP19A1SLC6A4SLC6A2HRH3
Hydrochloric Acid SCHEMBL7484921 0.83 HRH3 (0.45) OPRD1CYP19A1SLC6A4SLC6A2HRH3
SCHEMBL7156162 0.83 CYP19A1 (0.42) CYP19A1HRH3CPA1
SCHEMBL3501778 0.80 CHRM3 (0.46) CYP19A1SLC6A4SLC6A2CPA1
SCHEMBL7746101 0.80 CYP19A1 (0.43) CYP19A1SLC6A4HRH3
SCHEMBL3500628 0.80 FNTA (0.54) CYP19A1OPRM1CPA1P2RX7
SCHEMBL7188902 0.79 CYP19A1 (0.41) CYP19A1SLC6A4SLC6A2SLC1A3SLC1A2
SCHEMBL3515229 0.78 MEN1 (0.42) CYP19A1MEN1KMT2ACPA1
SCHEMBL7483971 0.77 FNTA (0.47) CYP19A1MEN1KMT2A
SCHEMBL5552211 0.77 HRH3 (0.41) CYP19A1SLC6A4HRH3CPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1019529-A4 A METHOD OF TREATING CANCER MERCK & CO INC (US) 2002-09-11 EP claimed
JP-2001518281-A 2001-10-16 JP claimed
EP-1019529-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 2000-07-19 EP claimed
EP-1009854-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 2000-06-21 EP claimed
WO-1999010525-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1999-03-04 WO claimed
WO-1999010523-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1999-03-04 WO claimed
EP-1019529-A4 A METHOD OF TREATING CANCER MERCK & CO INC (US) 2002-09-11 EP disclosed
US-6103487-A DETECTING MODULATORS THAT SUPPRESS THE ACTIVITY OF A TRANSFERASES; ANTICARCINOGENIC AGENTS MERCK & CO., INC. (US) 2000-08-15 US disclosed
EP-1019530-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 2000-07-19 EP disclosed
EP-1019529-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 2000-07-19 EP disclosed
EP-1009854-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 2000-06-21 EP disclosed
WO-2000016626-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 2000-03-30 WO disclosed
WO-1999010525-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1999-03-04 WO disclosed
WO-1999010524-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1999-03-04 WO disclosed
WO-1999010523-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1999-03-04 WO disclosed